Relapsing Multiple Sclerosis
EMD SERONO
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Aubagio, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety.
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Aubagio, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety.
